ResearchPUBMED3 days ago
Researchers in Switzerland studied how many adults with inherited metabolic diseases (rare conditions where the body cannot break down certain substances properly) were able to get orphan drugs (special medicines made for rare diseases). They looked at records from 2017 to 2022 to understand which patients received these medicines, how long it took to get them approved and paid for, and what rules made it easier or harder to access them.
WHY IT MATTERSIf you have an inherited metabolic disease in Switzerland or Europe, this study shows real-world timelines for how long it typically takes to get orphan drug approval and reimbursement—information that can help you advocate for faster access with your doctor and insurance company.
PipelineRSSMay 5
European regulators have approved a special status for SGT-003, a new gene therapy treatment for Duchenne muscular dystrophy (DMD), a serious muscle disease that affects boys. This approval, called orphan drug designation, means the treatment is recognized as addressing a rare disease with few other options. The therapy is designed to help preserve muscle strength in boys with DMD.
WHY IT MATTERSSGT-003 now has regulatory backing in both the U.S. and Europe, which accelerates its development pathway and may bring a new treatment option closer to boys with DMD who currently have limited gene therapy choices.
ResearchPUBMEDMay 1
Researchers studied patent applications from China between 1995 and 2023 to understand how many new orphan drugs (medicines for rare diseases) are being developed there. They found that China filed 58% more patent applications for rare disease treatments between 2018 and 2023, with most focus on cancer and brain diseases. This shows China is investing more in rare disease research, especially after new government policies were put in place.
WHY IT MATTERSPatients with rare diseases in China and globally benefit when more countries invest in orphan drug development, as increased competition and innovation can lead to more treatment options and potentially lower costs.
ResearchPUBMEDMay 1
Researchers looked at how the FDA approves medicines for rare diseases from 2020 to 2024. They found that 129 rare disease drugs were approved during this time, and 25 of them (about 19%) used real-world data—information collected from patients outside of traditional clinical trials. Real-world data is becoming more important for rare diseases because it's often impossible to run large traditional studies when so few people have a disease.
WHY IT MATTERSIf you have a rare disease, this research shows the FDA is increasingly accepting real-world evidence from patient experiences and medical records to approve new treatments, which could mean faster access to medicines when traditional large-scale trials aren't feasible.
ResearchPUBMEDApr 5
Researchers looked at studies from 2014 to 2024 about the cost and value of special medicines for rare kidney diseases in poorer countries. They found that there isn't much research on whether these expensive medicines are worth the money in these areas. The study shows that doctors and governments need better information to decide if patients should have access to these treatments.
WHY IT MATTERSIf you have a rare kidney disease in a low- or middle-income country, this research highlights why your access to orphan drugs is limited — there's a major gap in evidence about whether these treatments are affordable and effective in your region.